Multiple Sclerosis

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

Efficacy, safety and tolerability of an orally administered cannabis extractin the treatment of spasticity in patients with multiple sclerosis: arandomized, double-blind, placebo-controlled, crossover study

Smoked cannabis for spasticity in multiple sclerosis:a randomized, placebo-controlled trial

Sativex for the management of multiple sclerosis symptoms

 

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

 

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity

 

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors

 

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial

 

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis

 

Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis

 

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

 

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

 

Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain